Lingkang Pharmaceuticals (603669.SH) released its first-quarter performance, with a net loss attributable to shareholders of 18.62 million yuan.

Zh tng cijng APP xn, lng kng yoy (603669.SH) pl 2025 nin d y jd bogo, bogo q gngs shxin yngshu 5012 wn yun, tngb xijing 34.79%; gum jngll kusn 1862 wn yun; k fi jngll kusn 1791 wn yun. Jbn mi g shuy -0.03 yun. According to the Zhutong Finance APP, Lingkang Pharmaceutical (603669.SH) disclosed the first quarter report of 2025, with the company's revenue reaching 50.12 million yuan, a year-on-year decrease of 34.79%; net profit attributable to shareholders was a loss of 18.62 million yuan; non-recurring net profit was a loss of 17.91 million yuan. Basic earnings per share was -0.03 yuan.